Stefan Rödiger
@pangolin@openscience.network

Prof. & Researcher focused on #Bioanalytics, #Bioinformatics, #Pharma, Human #diagnostics (#LiquidBiopsy) and a bit #Forensics

Website
www.b-tu.de/en/fg-multiparameterdiagnostik/rg-roediger
Other profiles
0000-0002-1441-6512
Liz Hare PhD
@lizhare@fosstodon.org  ·  activity timestamp 2 days ago
Egon Willigh☮gen 🟥
@egonw@mastodon.social  ·  activity timestamp 4 days ago
elias
@elias@fediscience.org  ·  activity timestamp last week
Screenshot of Openalex' statement. The most important part: We’re pausing the alpha, effective now; you’ll no longer be able to use or query the Analytics. We’re doing this for two reasons: We’ve learned how expensive it is to answer these complex ad-hoc queries. Our current numbers suggest we’d need to charge you and other users about $50k/yr, and our research indicates there’s no market at this price point (that said, if we’re wrong and you’ve got $50k/yr for this, let us know…our minds can be changed 😁). I think we need to figure out a way to do Analytics more cheaply to make it viable—either use a cheaper technology or support less flexibility. We’ve got some ideas on both counts, but we need time to look into it. Which brings us to… We need to focus on the new OpenAlex rewrite launch over the next few months. This is the biggest project we’ve ever done and we need to really zone in or it’s not going to work. So we’re saying “no” to everything we possibly can in Q4, so that we can say a great big “yes” to making OpenAlex faster, more accurate, and more comprehensive (we’re passing 400M works!). We’ll return to Analytics in 2026 with a new approach, probably one integrated more tightly with the existing UI and definitely one taking advantage of our turbocharged new backend architecture.
Screenshot of Openalex' statement. The most important part: We’re pausing the alpha, effective now; you’ll no longer be able to use or query the Analytics. We’re doing this for two reasons: We’ve learned how expensive it is to answer these complex ad-hoc queries. Our current numbers suggest we’d need to charge you and other users about $50k/yr, and our research indicates there’s no market at this price point (that said, if we’re wrong and you’ve got $50k/yr for this, let us know…our minds can be changed 😁). I think we need to figure out a way to do Analytics more cheaply to make it viable—either use a cheaper technology or support less flexibility. We’ve got some ideas on both counts, but we need time to look into it. Which brings us to… We need to focus on the new OpenAlex rewrite launch over the next few months. This is the biggest project we’ve ever done and we need to really zone in or it’s not going to work. So we’re saying “no” to everything we possibly can in Q4, so that we can say a great big “yes” to making OpenAlex faster, more accurate, and more comprehensive (we’re passing 400M works!). We’ll return to Analytics in 2026 with a new approach, probably one integrated more tightly with the existing UI and definitely one taking advantage of our turbocharged new backend architecture.
Screenshot of Openalex' statement. The most important part: We’re pausing the alpha, effective now; you’ll no longer be able to use or query the Analytics. We’re doing this for two reasons: We’ve learned how expensive it is to answer these complex ad-hoc queries. Our current numbers suggest we’d need to charge you and other users about $50k/yr, and our research indicates there’s no market at this price point (that said, if we’re wrong and you’ve got $50k/yr for this, let us know…our minds can be changed 😁). I think we need to figure out a way to do Analytics more cheaply to make it viable—either use a cheaper technology or support less flexibility. We’ve got some ideas on both counts, but we need time to look into it. Which brings us to… We need to focus on the new OpenAlex rewrite launch over the next few months. This is the biggest project we’ve ever done and we need to really zone in or it’s not going to work. So we’re saying “no” to everything we possibly can in Q4, so that we can say a great big “yes” to making OpenAlex faster, more accurate, and more comprehensive (we’re passing 400M works!). We’ll return to Analytics in 2026 with a new approach, probably one integrated more tightly with the existing UI and definitely one taking advantage of our turbocharged new backend architecture.
Dan Goodman
@neuralreckoning@neuromatch.social  ·  activity timestamp 6 days ago
DFG
@dfg_public@wisskomm.social  ·  activity timestamp 7 days ago
ORCID Organization
@ORCID_Org@scicomm.xyz  ·  activity timestamp last week
Stefan Rödiger
@pangolin  ·  activity timestamp 7 days ago
CytoBead ANA 2 Slide Format This image illustrates the CytoBead ANA 2 slide format, designed for the simultaneous screening and confirmation of antinuclear antibodies (ANA) and ANA-specific autoantibodies. - Central Compartment: Contains HEp-2 cells, which are used for the initial screening of ANA via indirect immunofluorescence. The presence of autoantibodies is indicated by fluorescence patterns on these cells. - Peripheral Compartments: Surrounding the central HEp-2 cell compartment are four smaller compartments, each containing antigen-coated fluorescent microbeads. These compartments are used for the confirmatory detection of specific autoantibodies: - Compartment 1: Contains SS-B/La-coated beads (9 µm) and Jo-1-coated beads (15 µm). - Compartment 2: Contains Sm-coated beads (9 µm) and Sm/RNP-coated beads (15 µm). - Compartment 3: Contains dsDNA-coated beads (9 µm) and Scl-70-coated beads (15 µm). - Compartment 4: Contains SS-A/Ro60-coated beads (9 µm) and SS-A/Ro52-coated beads (15 µm). Reference Beads: Size and location reference (SLR) beads are present in all peripheral compartments to assist in the identification and localization of the antigen-coated microbeads. This layout allows for both the screening of ANA on HEp-2 cells and the simultaneous confirmation of specific autoantibodies using antigen-coated microbeads, streamlining the diagnostic process.
CytoBead ANA 2 Slide Format This image illustrates the CytoBead ANA 2 slide format, designed for the simultaneous screening and confirmation of antinuclear antibodies (ANA) and ANA-specific autoantibodies. - Central Compartment: Contains HEp-2 cells, which are used for the initial screening of ANA via indirect immunofluorescence. The presence of autoantibodies is indicated by fluorescence patterns on these cells. - Peripheral Compartments: Surrounding the central HEp-2 cell compartment are four smaller compartments, each containing antigen-coated fluorescent microbeads. These compartments are used for the confirmatory detection of specific autoantibodies: - Compartment 1: Contains SS-B/La-coated beads (9 µm) and Jo-1-coated beads (15 µm). - Compartment 2: Contains Sm-coated beads (9 µm) and Sm/RNP-coated beads (15 µm). - Compartment 3: Contains dsDNA-coated beads (9 µm) and Scl-70-coated beads (15 µm). - Compartment 4: Contains SS-A/Ro60-coated beads (9 µm) and SS-A/Ro52-coated beads (15 µm). Reference Beads: Size and location reference (SLR) beads are present in all peripheral compartments to assist in the identification and localization of the antigen-coated microbeads. This layout allows for both the screening of ANA on HEp-2 cells and the simultaneous confirmation of specific autoantibodies using antigen-coated microbeads, streamlining the diagnostic process.
CytoBead ANA 2 Slide Format This image illustrates the CytoBead ANA 2 slide format, designed for the simultaneous screening and confirmation of antinuclear antibodies (ANA) and ANA-specific autoantibodies. - Central Compartment: Contains HEp-2 cells, which are used for the initial screening of ANA via indirect immunofluorescence. The presence of autoantibodies is indicated by fluorescence patterns on these cells. - Peripheral Compartments: Surrounding the central HEp-2 cell compartment are four smaller compartments, each containing antigen-coated fluorescent microbeads. These compartments are used for the confirmatory detection of specific autoantibodies: - Compartment 1: Contains SS-B/La-coated beads (9 µm) and Jo-1-coated beads (15 µm). - Compartment 2: Contains Sm-coated beads (9 µm) and Sm/RNP-coated beads (15 µm). - Compartment 3: Contains dsDNA-coated beads (9 µm) and Scl-70-coated beads (15 µm). - Compartment 4: Contains SS-A/Ro60-coated beads (9 µm) and SS-A/Ro52-coated beads (15 µm). Reference Beads: Size and location reference (SLR) beads are present in all peripheral compartments to assist in the identification and localization of the antigen-coated microbeads. This layout allows for both the screening of ANA on HEp-2 cells and the simultaneous confirmation of specific autoantibodies using antigen-coated microbeads, streamlining the diagnostic process.